Chronic Obstructive Pulmonary Disease

AstraZeneca in $560 m deal for respiratory firm

British drugmaker AstraZeneca PLC says it is to acquire Pearl Therapeutics Inc., a Redwood-City, California-based company involved in therapies for asthma and chronic obstructive pulmonary disease for at least $560 million.

Jun 10, 2013
popularity not rated yet | comments 0

New factor to control oncogene-induced senescence

An article published on the journal Nature describes the major role that Pyruvate dehydrogenase (PDH) —an enzyme of cellular energy metabolism— plays in the regulation of the cellular senescence induce ...

May 21, 2013
popularity not rated yet | comments 0

Latest Spotlight News